Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK+ Non-Small-Cell Lung Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableActive Not RecruitingNCT05735327
What this trial is testing

Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda 50
Early research (Phase 1)Study completedNCT01772797
What this trial is testing

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

Who this might be right for
Anaplastic Lymphoma Kinase (ALK)Non-small Cell Lung Cancer
Novartis Pharmaceuticals 22
Not applicableUnknownNCT05110950
What this trial is testing

Endobronchial Ultrasound Needle Aspiration With and Without Suction

Who this might be right for
Mediastinal LymphadenopathyHilar LymphadenopathyLymphoma+7 more
Università Politecnica delle Marche 306
Testing effectiveness (Phase 2)UnknownNCT04641754
What this trial is testing

A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 176
Testing effectiveness (Phase 2)Study completedNCT04111705
What this trial is testing

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Intergroupe Francophone de Cancerologie Thoracique 23
Early research (Phase 1)Ended earlyNCT01121588
What this trial is testing

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Who this might be right for
Neoplasms Malignant
Pfizer 44
Testing effectiveness (Phase 2)UnknownNCT05178511
What this trial is testing

Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance

Who this might be right for
The Diagnosis Was ALK Positive NSCLCSecond Generation ALK-TKI is ResistantEfficacy of Ensatinib in This Subset of Patients
Li Zhang, MD 40
Testing effectiveness (Phase 2)UnknownNCT05296278
What this trial is testing

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 70
Not applicableNot Yet RecruitingNCT07674524
What this trial is testing

Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)HyperlipidemiaALK Gene Mutation+1 more
Sun Yat-sen University 160
Testing effectiveness (Phase 2)UnknownNCT05380024
What this trial is testing

Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Peking University Cancer Hospital & Institute 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT05740943
What this trial is testing

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Who this might be right for
Stage III NSCLCSurgery
Guangdong Provincial People's Hospital 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT03753685
What this trial is testing

X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Who this might be right for
Nonsmall Cell Lung CancerBrain Metastases
Fudan University 27
Not applicableStudy completedNCT01662635
What this trial is testing

Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)

Who this might be right for
Non Small-cell Lung Cancer
Instituto Nacional de Cancerologia de Mexico 230
Early research (Phase 1)Active Not RecruitingNCT03611738
What this trial is testing

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Who this might be right for
Non-small Cell Lung CancerLung CancerNon-small Cell Lung Cancer Metastatic+3 more
H. Lee Moffitt Cancer Center and Research Institute 21
Early research (Phase 1)Study completedNCT05055232
What this trial is testing

A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

Who this might be right for
ROS1 Rearrangement Non-small Cell Lung CancerALK Rearrangement Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 114
Large-scale testing (Phase 3)Study completedNCT03194893
What this trial is testing

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Who this might be right for
Neoplasms
Hoffmann-La Roche 50
Testing effectiveness (Phase 2)UnknownNCT05482087
What this trial is testing

XZP-3621 in Chinese Patients With ALK Positive NSCLC

Who this might be right for
ALK-positive NSCLC
Xuanzhu Biopharmaceutical Co., Ltd. 190
Testing effectiveness (Phase 2)Study completedNCT02048488
What this trial is testing

A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

Who this might be right for
Solid TumorsLymphomas
Tesaro, Inc. 72
Early research (Phase 1)Ended earlyNCT04849273
What this trial is testing

TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung CancerNon-Small Cell Lung CancerNSCLC+3 more
Turning Point Therapeutics, Inc. 11
Not applicableStudy completedNCT04592523
What this trial is testing

Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

Who this might be right for
Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma Kinase
Takeda 271
Next Page